CryoPort (NASDAQ:CYRX) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

03 Mar 2026, 18:18 by Teresa Graham · The Cerbat Gem

CryoPort (NASDAQ:CYRX – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08), FiscalAI reports. The business had revenue of $45.45 million for the quarter, compared to analysts’ expectations of $42.92 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%.

CryoPort Stock Up 3.4%

Shares of CYRX stock traded up $0.28 during trading hours on Tuesday, reaching $8.49. 774,827 shares of the company’s stock were exchanged, compared to its average volume of 355,364. The company has a current ratio of 15.77, a quick ratio of 15.01 and a debt-to-equity ratio of 0.40. The company has a market cap of $425.09 million, a price-to-earnings ratio of 7.26 and a beta of 1.69. CryoPort has a fifty-two week low of $4.58 and a fifty-two week high of $11.45. The stock’s 50 day moving average is $9.54 and its 200-day moving average is $9.41.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CYRX. Needham & Company LLC raised their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. UBS Group upped their price objective on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CryoPort has a consensus rating of “Moderate Buy” and an average target price of $12.83.

View Our Latest Stock Analysis on CYRX

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 11,570 shares of the business’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares in the company, valued at $806,772.42. The trade was a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On CryoPort

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its holdings in CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock valued at $31,150,000 after acquiring an additional 623,896 shares during the last quarter. Vanguard Group Inc. grew its position in shares of CryoPort by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after purchasing an additional 69,550 shares in the last quarter. UBS Group AG grew its position in shares of CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after purchasing an additional 705,649 shares in the last quarter. Mak Capital One LLC increased its holdings in shares of CryoPort by 46.6% in the fourth quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after purchasing an additional 381,063 shares during the last quarter. Finally, State Street Corp lifted its position in CryoPort by 0.8% during the fourth quarter. State Street Corp now owns 971,041 shares of the company’s stock worth $9,322,000 after buying an additional 7,254 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.